Posted by Michael Wonder on 07 Nov 2018
U.S. FDA approves Empliciti (elotuzumab) plus pomalidomide and dexamethasone, a new immunotherapy combination for certain patients with relapsed or refractory multiple myeloma
6 November 2018 - In the ELOQUENT-3 trial, treatment with Empliciti plus pomalidomide and dexamethasone doubled median progression-free survival and overall response rate versus pomalidomide and dexamethasone.
Bristol-Myers Squibb today announced that the U.S. FDA approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
Following priority review by the FDA, EPd is the first triplet combination to be approved based on a randomized clinical trial using Pd as a comparator.
